The Firm | Giving Back

Outcome Capital is proud of our commitment and donation to philanthropic activities spanning the life sciences ecosystem to further the advancement of science, medicine and the community, for the benefit of those who are suffering. We are excited to partner with like-minded entities and support their goals and mission to improve the practice of medicine and bring novel therapies to underserved patient populations.

We are embarking on a mission to raise a total of $2 million to directly fund a clinical trial for a promising new treatment for Langerhans Cell Histiocytosis (LCH), developed by a group of leading LCH physicians and scientists at Dana Farber Cancer Institute.

LCH is a rare disorder that occurs when a child has too many of a certain type of cell called Langerhans cells. These cells normally reside in the skin and help fight infection and destroy foreign substances in the body. In LCH, extra Langerhans cells spread through the blood and build up in certain parts of the body, where they can damage tissue or form tumors. While Langerhans cells typically accumulate in bones, they can also accumulate in the skin, lymph nodes, liver, spleen, lung, or brain. Recent studies by scientists at Dana-Farber Cancer Institute have demonstrated a mutant oncogene, BRAF V600E, in more than half of LCH biopsy samples. This suggests that LCH is a type of neoplastic disease (a disease grouping that includes benign, pre-cancerous and cancerous growths). LCH is most common in young children under 10.